Atara Biotherapeutics, Inc.
2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
United States
805 623 4211
https://www.atarabio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 225
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Pascal Touchon D.V.M. | President, CEO & Director | 1.08M | 無 | 1963 |
| Mr. K. Amar Murugan | Executive VP & Chief Legal Officer | 618.52k | 無 | 1976 |
| Mr. Eric Hyllengren | Executive VP & Chief Financial Officer | 無 | 無 | 1976 |
| Dr. Anhco Nguyen Ph.D. | Executive VP and Chief Scientific & Technical Officer | 無 | 無 | 1973 |
| Alex Chapman | Vice President of Corporate Communications & Investor Relations | 無 | 無 | 無 |
| Ms. Jill Henrich | Executive VP and Global Head of Regulatory Affairs & Quality | 無 | 無 | 1963 |
| Mr. Dan Maziasz | Executive VP & Chief Business Officer | 無 | 無 | 無 |
| Ms. Rajani Dinavahi M.D. | Senior VP & Chief Medical Officer | 無 | 無 | 無 |
描述
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
公司管治
截至 2024年4月1日 止，Atara Biotherapeutics, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：6；董事會：5；股東權利：8；現金賠償：7。
